Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.58 |
| ▸ | AR | P10275 | 6/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | SHBG | P04278 | 1/20 | 0.48 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16016504 | 1.00 | PGR (0.67) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL13918110 | 1.00 | PGR (0.67) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL12473404 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL13918130 | 0.88 | PGR (0.79) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL15354859 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL2168575 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL13918127 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL2168200 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| Demegestone SCHEMBL146550 | 0.87 | PGR (0.78) | PGRNR3C1ARCYP2C19LMNA | |
| Demegestone SCHEMBL6851326 | 0.87 | PGR (0.78) | PGRNR3C1ARCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111577-A1 | Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH | 2006-05-25 | — | — | US | claimed |
| EP-1613640-A2 | METHOD FOR PREPARING 17 ALPHA-ACETOXY-11 BETA-(4-N,N-DIMETHYLAMIN OPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004078709-A2 | METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-09-16 | — | — | WO | claimed |
| EP-3052513-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF ULIPRISTAL ACETATE AND ITS 4'-ACETYL ANALOGUE | RICHTER GEDEON NYRT (HU) | 2018-12-05 | — | — | EP | disclosed |
| EP-2774933-B1 | ULIPRISTAL ACETATE PREPARATION METHOD AND INTERMEDIATE THEREOF | UTOPHARM (SHANGHAI) CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-9676814-B2 | Industrial process for the synthesis of ulipristal acetate and its 4′-acetyl analogue | RICHTER GEDEON NYRT. (HU) | 2017-06-13 | — | — | US | disclosed |
| US-20160311849-A1 | Industrial Process for the Synthesis of Ulipristal Acetate and its 4'-Acetyl Analogue | RICHTER GEDEON NYRT. (HU) | 2016-10-27 | — | — | US | disclosed |
| EP-3052513-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF ULIPRISTAL ACETATE AND ITS 4'-ACETYL ANALOGUE | Richter Gedeon Nyrt. (HU) | 2016-08-10 | — | — | EP | disclosed |
| EP-2348031-B9 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9163058-B2 | Method for preparing ulipristal acetate and key intermediate thereof | UTOPHARM (SHANGHAI) CO., LTD (CN) | 2015-10-20 | — | — | US | disclosed |
| CN-104774231-A | 17alpha-hydroxy-19-norpregn-4,9-diene-3,20-dione preparation process | SHANGHAI INST PHARM INDUSTRY | 2015-07-15 | — | — | CN | disclosed |
| EP-0817793-A2 | METHOD FOR PREPARING 17ALPHA-ACETOXY-11BETA-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES. | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0422100-B1 | 11 BETA-SUBSTITUTED PROGESTERONE ANALOGS | RES TRIANGLE INST (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1996030390-A2 | METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES. | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0422100-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| US-5073548-A | Antiprogestational, progestational and antiglucocorticoid activity; glandular disorders; vision defects; antifertility agents | RESEARCH TRIANGLE INSTITUTE (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0422100-A1 | 11-g(b)-SUBSTITUTED PROGESTERONE ANALOGS. | RES TRIANGLE INST (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4954490-A | HORMONE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 1990-09-04 | — | — | US | disclosed |
| WO-1989012448-A1 | 11beta-SUBSTITUTED PROGESTERONE ANALOGS | RESEARCH TRIANGLE INSTITUTE (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0245170-A1 | 19-Nor or 19-nor D-homo steroids substituted at position 11 beta by a phenyl group substituted by an alkynyl group, process for their preparation, their use in medicaments and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311849-A1 | Industrial Process for the Synthesis of Ulipristal Acetate and its 4'-Acetyl Analogue | AADAC, NAT1, UBA1 | PGR 2982/4885NR3C1 1696/4885AR 1535/4885 |
| US-20060111577-A1 | Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates | CYP17A1, CYP19A1, HSD17B11 | PGR 69/4885NR3C1 82/4885AR 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.